LONDON BROKER RATINGS: Citi cuts Severn Trent and United Utilities
5th May 2026 09:35
(Alliance News) - The following London-listed shares received analyst recommendations on Tuesday morning and on Monday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations on Tuesday morning and on Monday: Read More
(Alliance News) - The FTSE 100 closed down on Friday, but above early lows, while the oil price fell amid reports that Iran has made a new proposal amid stalled US peace talks. Read More
(Alliance News) - AstraZeneca PLC on Friday said it had secured a recommendation for its cancer drug Truqap from US authorities, but failed to secure a majority in favour of its treatment camizestrant. Read More
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Says the US Food & Drug Administration's Oncologic Drugs Advisory Committee recommended the benefit–risk profile of Truqap when used with abiraterone and hormone‑lowering therapy for PTen‑deficient metastatic hormone‑sensitive prostate cancer. AstraZeneca says the recommendation follows late‑stage trial results showing the combination helps delay disease progression. The company adds it is the first targeted treatment to show benefit in this form of the disease and notes the decision follows the FDA's earlier acceptance of its application. Truqap is a targeted treatment designed to block a growth pathway used by cancer cells. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday: Read More
(Alliance News) - The FTSE 100 closed lower on Wednesday, held back by falls in drugs firms GSK and AstraZeneca, while oil surged amid reports that the US is eyeing a longer blockade of the Strait of Hormuz. Read More
(Alliance News) - Cambridge, England-based pharmaceutical firm AstraZeneca PLC will pump GBP300 million into UK drugs development in a "major vote of confidence" in the country, the prime minister has said. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Wednesday. Read More
(Alliance News) - Stock prices in London opened lower on Wednesday, as renewed uncertainty in energy markets and a heavy slate of corporate updates weighed on sentiment ahead of the Fed's rate call. Read More
(Alliance News) - AstraZeneca PLC on Wednesday reported better-than-expected first-quarter revenue and profit, and flagged the potential for its drugs pipeline amid numerous positive trial findings and regulatory approvals. Read More
(Alliance News) - AstraZeneca, Lloyds Banking Group and GSK report higher earnings in the first quarter. Read More
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Breztri Aerosphere is approved by the US Food & Drug Administration as a maintenance treatment for asthma in patients 12 years and older. Breztri is a fixed-dose triple-combination therapy. It already was approved by the FDA in 2020 for the treatment of adults with chronic obstructive pulmonary disease. Astra says the new indication follows trials in which Breztri showed a "statistically significant and clinically meaningful improvement in lung function". Astra notes that Breztri is a maintenance therapy and isn't meant to replace a rescue inhaler to relieve sudden breathing problems. It says filings for Breztri in asthma are under review in the EU, Japan and China. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Monday. Read More
(Alliance News) - AstraZeneca PLC on Monday said its self-administered lupus treatment has been approved in the US. Read More
(Alliance News) - GSK reports on a US court ruling in ongoing litigation, AstraZeneca announces US approval for a self-administered lupus treatment, while Harworth Group receives planning consent for a data centre development in Leeds. Read More
(Alliance News) - The FTSE 100 ended the week on the back foot as the crisis in the Middle East remained deadlocked. Read More
AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Rene Haas will step down as a non-executive director on Thursday next week, the end of April, due to his increased executive duties. Haas is the chief executive officer of UK-based computer-chip designer Arm Holdings PLC and earlier this week was named to the additional role of CEO of SoftBank Group International. Japanese technology investor SoftBank Group Corp remains a major shareholder in Arm following its New York listing in 2023, retaining a 90% stake at the time. Read More
(Alliance News) - AstraZeneca PLC on Tuesday reported positive findings from trial results studying its kidney disease treatment, Ultomiris. Read More
(Alliance News) - AstraZeneca PLC on Monday reported positive phase three results for its monoclonal antibody, Tozorakimab, meeting its primary endpoint in the Miranda trial in patients with chronic obstructive pulmonary disease. Read More